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Primary hyperoxaluria type 1 (PH1) is a rare genetic
disorder characterized by allelic and clinical heterogeneity.
We aim to describe the presentation and full single-center
experience of the management of PH1 patients bearing
the mutation described in our community (I244T
mutationþpolymorphism P11L). Since 1983, 12 patients
with recurrent renal lithiasis have been diagnosed with PH1
and renal failure in the Canary Islands, Spain. Diagnostic
confirmation was based on the presence of oxalosis in
undecalcified bone or kidney allograft biopsy, reduced
alanine:glyoxylate aminotransferase activity in liver biopsy,
and blood DNA analysis. Patients underwent different
treatment modalities depending on individual clinical
circumstances and therapeutic possibilities at the time of
diagnosis: hemodialysis, isolated kidney, simultaneous
liver–kidney, or pre-emptive liver transplantation. In all cases,
the presentation of advanced renal disease was relatively late
(413 years) and no cases were reported during lactancy or
childhood. The eight patients treated with hemodialysis
or isolated kidney transplantation showed unfavorable
evolution leading to death over a variable period of time.
In contrast, the four patients undergoing liver
transplantation (three liverþ kidney and one pre-emptive
liver alone) showed favorable long-term allograft and patient
survival (up to 12 years follow-up). In conclusion, in this PH1
population, all bearing the I244T mutation, the development
of end-stage renal disease was distinctive during late
adolescence or adulthood. Our long-term results support
pre-emptive liver transplantation at early stages of renal
failure, and kidney–liver transplantation for those with
advanced renal disease.
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Primary hyperoxaluria type 1 (PH1) is a rare autosomal-
recessive disorder characterized by a functional defect of
the liver peroxisomal enzyme alanine:glyoxylate aminotrans-
ferase, which shows considerable phenotypic and genotypic
heterogeneity.1,2 Its estimated prevalence is over a broad
range of 1–2.9 per million population.3,4 In the Canary
Islands, an Atlantic overseas region of Spain, we have
observed a disproportionately high prevalence of PH1.5,6
Strikingly, a large percentage of these patients are originally
from one small island, that of La Gomera with approximately
17 000 inhabitants5 (Figure 1). Recently, we have identified
the Ile-244-Thr (I244T) mutation in the AGXT gene in our
PH1 patients or their relatives. In these cases, hyperoxaluria
results from I244T mutation in combination with the
common polymorphism Pro-11-Leu (P11L).7 This dis-
order constitutes an example of protein conformational
disease, where misfolded proteins form functionally inactive
aggregates.7
As this enzyme is only expressed in the liver,2 this
metabolic defect can only be treated by liver transplantation.
In PH1 patients with end-stage renal disease (ESRD),
simultaneous liver–kidney transplantation, first reported in
1987,8 is currently considered the treatment of choice.9–12 For
patients without advanced renal disease, pre-emptive liver
transplantation is the definitive treatment, although current
experience is very limited and mainly reported in young
children and infants.13–17
Our aim was to describe the full single-center experience
in the management of adult patients with PH1 and renal
disease during the last two decades. Of particular considera-
tion, all our patients were late adolescents or adults, bearing
the same genetic mutation, and were managed according to
the therapeutic resources available at the time of diagnosis.
RESULTS
Clinical and genetic data, as well as patient evolution during
dialysis or after transplantation, are shown in Tables 1 and 2.
Family antecedents of renal stone formation were established
for nine patients, and was doubtful or unknown in other
patients. Parental consanguinity was verified in the three
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Figure 1 | Map showing geographic location of Canary Islands.
Table 1 | PH1 patients who did not receive liver transplant
Agea
Case Sex Diagnostic confirmation Mutation Evolution Cause of death
1 19 Bone biopsy Homozygous I244T Died after 1.5 years on HD Oxalosis
M Complications
2 41 Bone biopsy Unknown Died after 8 years on HD Oxalosis
M Complications
3 38 Bone biopsy Homozygous I244T KTx failed (relapse of oxalosis) Oxalosis
M Died after 7 years on HD Complications
4 18 Bone biopsy Homozygous I244T 3 years on HD Oxalosis+sepsis CMV
F KTx biopsy Died 8 months after KTx
5 42 KTx biopsyb Homozygous I244T 1 year on HD Sepsis Pn Carinii
F Died 3 months after KTx
6 20 Bone biopsy Homozygous I244T 2.5 years on HD Oxalosis
M Died 14 months after KTx Complications
7 34 1st KTx biopsyb Homozygous I244T 1 year on HD Late oxalosis complications
M 11 KTx survived 5 years, relapse of oxalosis
21 KTx survived 8 years, relapse of oxalosis
Died after 2 years on HD
8 60 KTx biopsyb Compound heterozygous
G170R and I244T
1 year on HD Still living on HD
F KTx failed, relapse of oxalosis
CMV, cytomegalovirus; HD, hemodialysis; F, female; KTx, kidney allograft transplantation; M, male; PH1, primary hyperoxaluria type 1.
aAge at the initiation of HD in years.
bDiagnosed after KTx.
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affected brothers (Patients 1, 9, and 10) and in two other
cases (Patients 6 and 11).
The first clinical manifestations were renal colic and
calculi passage in all patients except Patient 12, who
commenced with nephrocalcinosis and renal failure. The
age of onset was variable: lactancy and childhood in seven
patients, adolescence and early adulthood in two cases, and
during the fourth decade of life in the two remaining
patients. Nephrocalcinosis was detected in all cases. Mani-
festations of obstructive uropathy occurred in most patients
and seven patients required some kind of intervention,
including surgery or lithotripsy. Hence, one patient under-
went unilateral nephrectomy 1 year after liver–kidney
transplantation (Patient 9) and another bilateral nephrect-
omy while on hemodialysis (Patient 6).
Hyperoxaluria was documented in four patients with vari-
able degrees of renal failure (Patients 6 and 9–11). Patient 10
showed absolute resistance to pyridoxine and antilithogenic
therapy, despite being treated at an early stage. In Patient 12,
high urinary excretion of oxalate and glycolate was evident after
the first kidney transplantation, which failed shortly thereafter.
Advanced renal failure developed relatively late in this
population. There were no cases of ESRD during lactancy or
childhood; one patient (number 12) initiated dialysis at
13 years of age and the rest during adulthood, from 18 up to
62 years of age.
Table 1 shows the outcome of eight patients treated with
hemodialysis or renal transplantation alone. All six isolated
renal transplants failed owing to ongoing oxalate production
and recurrent disease. Most of these eight patients developed
progressive bone disease, mimicking renal osteodystrophy
but with inappropriate osteosclerosis and progressive dis-
ability. Clinical manifestation of systemic oxalosis appeared
over a variable period of time. The main complications were
bone and joint pain, polyneuropathy, and arrythmia
presumed to be secondary to myocardial oxalate deposition.
Systemic oxalosis was extremely severe in Patient 1, who
evolved with bone deformities, opiaceous-dependent bone
and joint pain, and absolute disability. Over the first 2 years
on hemodialysis, the patient suffered ischemic necrosis of
several phalanges, spontaneous loss of teeth, and diffuse
extraosseous calcifications. Patient 12 showed retarded
growth, responding minimally to growth hormone therapy
before liver–kidney transplantation. As reflected in the table,
the diagnosis of PH1 was confirmed by bone biopsy (n¼ 6)
or renal allograft biopsy (n¼ 2).
Table 2 shows data of patients who received simultaneous
liver–kidney (n¼ 3) or pre-emptive liver transplantation
(n¼ 1). Patients who underwent liver–kidney transplantation
received aggressive pre-transplant hemodialysis and there
were no cases of post-transplant acute tubular necrosis. There
was no long-term morbidity associated with the transplanta-
tion procedure. At the close of this study, all kidney and liver
allografts were still functioning. Oxaluria remained below
40 mg/24 h in all cases and serum creatinine remained very
close to the normal range in all patients, except Patient 9.
This patient had urological complications – unrelated to PH1
– and chronic renal failure, but he remains free of dialysis
after 12 years of follow-up.
DISCUSSION
PH1 is a rare genetic disorder characterized by allelic and
clinical heterogeneity. For this reason, it is extremely difficult
to establish a correlation between the genetic profile and the
clinical presentation. Previous reports, mainly based on renal
patient registries, have reported that PH1 presents in
approximately 10% of affected individuals very early during
lactancy or childhood, 80–90% in late childhood or early
adolescence, and fewer than 10% of affected individuals
present in adulthood.17
Table 2 | PH1 patients who received simultaneous liver–kidney (L–K Tx) or pre-emptive liver transplantation (LTx)
Case
Agea
Sex
Diagnostic
confirmation Mutation
Vintage
Date and type of Tx Graft evolution (immunosuppression)
9 25 Brother of Case 1 Homozygous I244T 2 years on HD Functioning at 12 years
M Liver biopsy. 1993 L–K Tx Tacrolimus+prednisone
sCre: 4.1 mg/dl
10 23 Brother of Case 1 Homozygous I244T 1994 Pre-emptive LTx Functioning at 11 years
M Hyperoxaluria Ciclosporine (monotherapy)
sCre: 1.2 mg/dl
11 19 Liver biopsy Homozygous I244T 1 year on HD Functioning at 8 years
F 1997 L–K Tx Cyclosporine+prednisone
sCre: 1.2 mg/dl
12 16 KTx biopsyb Homozygous I244T 3 months on HD Functioning at 4 years
M RTx failed. Tacrolimus+prednisone+mycophenolate
18 months on HD sCre: 1.1 mg/dl
2001 L–K Tx
HD, hemodialysis; F, female; KTx, kidney allograft transplantation; M, male; PH1, primary hyperoxaluria type 1; sCre, serum creatinine.
aAge at the time of transplantation (years).
bDiagnosed after KTx.
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To date, over 50 different mutations and seven poly-
morphisms have been identified, and some of them have been
related with either pyridoxine responsiveness or very early
development of ESRD.18–20 These studies have shown that
mutation analysis may help to predict the clinical course and
to define the best therapeutic strategy. In our community, we
were able to follow patients with the same genetic mutation,
and interestingly, recurrent renal lithiasis and ESRD appeared
relatively late in this series, between the second and sixth
decade of life. To our knowledge, cases of PH1 developing to
advanced renal failure during lactancy or childhood have not
been observed or reported by the relatives in our region. Our
data suggest that this genetic variant of PH1 seems to be
associated with severe renal stone disease and ESRD, but of
relatively late presentation. However, we were unable to
ascertain pyridoxine response in this mutation, as only one
patient was attended at an early stage of renal failure (Case
10). This case showed an absolute resistance to doses of
pyridoxine up to 15 mg/kg/day.
Strategies for treating patients with PH1 include reduction
of oxalate production, antilithogenic measures, treatment of
systemic oxalosis by dialysis and/or kidney transplantation,
and cure of the metabolic defect by liver transplantation.
Management protocols in PH1 applying classic conserva-
tive measures have proved to be relatively effective in patients
who have not yet developed advanced renal failure.21–23
However, in patients with severe lithiasis and early renal
failure, these measures are often insufficient and patients
inevitably require renal replacement therapy. All authors
agree that treatment with hemodialysis6,23,24 is discouraging,
particularly in severe cases. After isolated renal transplanta-
tion, recurrence of oxalosis is the norm,6,24,25 although
acceptable results have been reported in selected patients
applying intensive protocols during the peri-transplant
period.22,26 These strategies should probably be reserved for
less severe cases where irreversible renal failure appears after
the fifth or sixth decades of life.
Liver transplantation is currently the treatment of choice
to correct the underlying disease. To date, most liver
transplantation has been performed after or simultaneously
with renal transplantation.9–12 The first pre-emptive liver
transplant was performed in 1989.13 Since then, several
isolated cases have been reported with successful results, most
of them in young children and infants.13–17 To date, all
available information on kidney–liver or pre-emptive liver
transplantation is based on patient registries or case series.17
Although published results are really encouraging, caution
should be exercised because some PH1 patients receiving
transplantation may be unreported, in particular those with
unfavorable outcomes. The recent availability of an inter-
national registry for primary hyperoxaluria (http://mayore-
search.mayo.edu/mayo/research/nephrology/registry.cfm)
should greatly improve data collection and analysis.
This single-center experience shows the complete out-
comes (favorable and unfavorable) of different therapeutic
modalities, applied to adult patients with advanced PH1 over
different periods of time. Although rigorous comparison of
therapeutic strategies is not possible, the frustrating results
obtained using more conservative strategies clearly contrast
with the favorable long-term outcomes observed in patients
who underwent liver transplantation. One limitation of our
study is that patients were diagnosed late in the course of the
disease, when referred to our hospital. We can only speculate
that early diagnosis and the application of prompt con-
servative measures might have affected the phenotype.
Indeed, the cases with the favorable outcome were also those
with the better diagnostic evaluation and more adequate
treatment. Our results underscore that early diagnosis is
crucial in PH1 patients to ensure proper treatment and the
best outcome possible.
The form of PH1 described in our community constitutes
a type of protein conformational disease, in which the
synergistic effect of a common polymorphism (P11L) and a
founder mutation (I244T) results in a misfolded protein that
tends to form inactive aggregates.7 In principle, this entity
may benefit from new early cell-based therapies with
pharmacological chaperones or small molecules to minimize
protein aggregation.7 Meanwhile, our long-term results in
adult patients provide additional and strong support for an
early inclusion in programs of pre-emptive liver transplanta-
tion or alternatively kidney–liver transplantation for those
with advanced or ESRD.
MATERIALS AND METHODS
Since 1983, 12 patients have been diagnosed with PH1 and advanced
renal failure in our hospital. We reviewed the clinical records of all
12 patients, the median age at initiation of hemodialysis was 29
years, ranging from 13 to 62 years; eight patients were men and four
women, all Caucasian. At the time of diagnosis of PH1, two patients
had moderate and advanced renal failure, respectively; six patients
were on maintenance hemodialysis; and four patients had under-
gone renal transplantation. Patients were treated with different
modalities according to individual clinical circumstances and
therapeutic possibilities. Treatment alternatives were hemodialysis
and kidney transplantation during the late 1980s, and simultaneous
kidney–liver or pre-emptive liver transplantation when possible
during the 1990s.
Diagnosis of primary hyperoxaluria
Given that most patients were studied and treated in the late 1980s
and 1990s, diagnosis was established by the resources available at
that time. Family history of renal colic, radiologic evidence of
calcium nephrolithiasis and/or nephrocalcinosis, and radiologic
osteosclerosis were the main diagnostic clues. Oxaluria detection
was used in only one case with residual renal function.
The presence of diffuse oxalate deposits in undecalcified bone
biopsy (Figure 2) or in kidney allografts, and decreased or absent
alanine:glyoxylate aminotransferase activity demonstrated in the
liver biopsy were the procedures used for diagnostic confirmation.
Undecalcified transiliac bone biopsies were obtained with
Bordier trephine after double tetracycline labeling applying a
standard technique.27 At that time, using this technique to study
renal osteodytrophy, we detected our first cases of PH1.
Alanine:glyoxylate aminotransferase enzymatic activity deter-
mined in liver biopsies28 was performed at a reference center
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(Department Chemical Pathology, University College of London)
for diagnostic confirmation (Cases 9 and 11).
Blood DNA was obtained from all patients and their relatives
when possible. In patients who had died, relatives were contacted to
obtain blood samples. DNA analysis was performed as described.5 In
one deceased patient (Case 2), genetic information was not
available. However, the patient came from the same region, which
suggests that he had the same genetic profile.
Informed consent to perform liver and/or kidney transplant was
obtained after a complete explanation of therapeutic options, risks,
and advantages.
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Figure 2 | Transiliac undecalcified bone specimen. (a) Marrow
granulomatous reaction constituted by multinucleated giant cells,
fibroblasts, and fibrosis (Masson–Goldner staining; out of focus areas
are hard to avoid in non-decalcified bone sections). (b) Highly
birefringent oxalate crystal deposition grouped in stars or rosette
(Toluidine blue staining viewed under polarized light).
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